ADMA BIOLOGICS, INC. Payments of Financing Costs
ADMA BIOLOGICS, INC. (ADMA) reported Payments of Financing Costs of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2026-02-25
- ADMA BIOLOGICS, INC. payments of financing costs for the quarter ending 2023-12-31 was $2.35M, a 3265177.78% increase year-over-year.
- ADMA BIOLOGICS, INC. payments of financing costs for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- ADMA BIOLOGICS, INC. payments of financing costs for the quarter ending 2023-06-30 was $0.00.
- ADMA BIOLOGICS, INC. payments of financing costs for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- ADMA BIOLOGICS, INC. payments of financing costs for fiscal 2025 was $0.00.
- ADMA BIOLOGICS, INC. payments of financing costs for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- ADMA BIOLOGICS, INC. payments of financing costs for fiscal 2023 was $2.35M, a 15.52% decline from fiscal 2022.
- ADMA BIOLOGICS, INC. payments of financing costs for fiscal 2022 was $2.78M.
| Period end | Payments of Financing Costs 3 month | Payments of Financing Costs 6 month | Payments of Financing Costs 9 month | Payments of Financing Costs 12 month | Payments of Financing Costs 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-25 | ||||
| 2024-12-31 | $0.00 10-K · filed 2026-02-25 | ||||
| 2023-12-31 | $2.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.35M derived: sum of 2 quarters · filed 2026-02-25 | $2.35M derived: sum of 3 quarters · filed 2026-02-25 | $2.35M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | $72.00 derived: sum of 4 quarters · filed 2025-03-18 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | $72.00 derived: sum of 3 quarters · filed 2025-03-18 | $404.63K derived: sum of 4 quarters · filed 2025-03-18 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-10 | $72.00 derived: sum of 2 quarters · filed 2025-03-18 | $404.63K derived: sum of 3 quarters · filed 2025-03-18 | $404.63K derived: sum of 4 quarters · filed 2025-03-18 | |
| 2022-12-31 | $72.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $404.63K derived: sum of 2 quarters · filed 2025-03-18 | $404.63K derived: sum of 3 quarters · filed 2025-03-18 | $2.78M 10-K · filed 2025-03-18 | $2.78M 10-K · filed 2023-03-23 |
| 2022-09-30 | $404.56K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $404.56K derived: sum of 2 quarters · filed 2023-11-08 | $2.78M 10-Q · filed 2023-11-08 | $2.78M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $2.38M 10-Q · filed 2023-08-09 | $2.38M derived: sum of 3 quarters · filed 2024-02-28 | $2.38M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-03-31 | $2.38M 10-Q · filed 2023-05-10 | $2.38M derived: sum of 2 quarters · filed 2024-02-28 | $2.38M derived: sum of 3 quarters · filed 2024-02-28 | $2.38M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $0.00 derived: sum of 2 quarters · filed 2024-02-28 | $0.00 derived: sum of 3 quarters · filed 2024-02-28 | $0.00 10-K · filed 2024-02-28 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $0.00 10-Q · filed 2022-08-10 | |||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |